AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23826214 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS of the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 18
Study 23826214 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS of the medial prefrontal cortex (MPFC)
Number of subjects: 18
Study 23826214 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study 19329547 — intervention group
Group type: COMPARATOR
Intervention: 50 mg LDX
Number of subjects: 36
Study 19329547 — intervention group
Group type: COMPARATOR
Intervention: 100 mg LDX
Number of subjects: 36
Study 19329547 — intervention group
Group type: COMPARATOR
Intervention: 150 mg LDX
Number of subjects: 36
Study 19329547 — intervention group
Group type: COMPARATOR
Intervention: 40 mg d-amphetamine
Number of subjects: 36
Study 19329547 — intervention group
Group type: COMPARATOR
Intervention: 200 mg diethylpropion
Number of subjects: 36
Study 17505429 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (ET) using Hemobahn/Viabahn endograft
Number of subjects: 42
Study 17505429 — intervention group
Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 42
Study 15730073 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based intervention
Number of subjects: 116
Study 15730073 — intervention group
Group type: COMPARATOR
Intervention: Standard advocate services alone
Number of subjects: 116
Study 12470020 — intervention group
Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 15
Study 12470020 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavit
Number of subjects: 15
Study 12470020 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract
Number of subjects: 15
Study 12470020 — intervention group
Group type: COMPARATOR
Intervention: Control (positive)
Number of subjects: 15
Study 12470020 — intervention group
Group type: COMPARATOR
Intervention: Control (negative)
Number of subjects: 15
Study 9447858 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ondansetron (50 microg/kg) plus dexamethasone (150 microg/kg)
Number of subjects: 197
Study 9447858 — intervention group
Group type: COMPARATOR
Intervention: High-dose ondansetron (150 microg/kg)
Number of subjects: 197
Study 8581393 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 Gy in 10 fractions (43 patients)
Number of subjects: 84
Study 8581393 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 Gy in 15 fractions (41 patients)
Number of subjects: 84
Study 2243152 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride 12.5 mg
Number of subjects: 144
Study 2243152 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride 25 mg
Number of subjects: 144
Study 2243152 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride 50 mg
Number of subjects: 144
Study 2243152 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride (all doses)
Number of subjects: 144
Study 2243152 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride
Number of subjects: 144
Study 369470 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 20
Study 369470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 369470 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 20
Study 30535716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fan Technique (FT)
Number of subjects: 6
Study 30535716 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Hand Technique (FH)
Number of subjects: 6
Study 28393632 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed about the gift card prize-draw incentive
Number of subjects: 433
Study 28393632 — intervention group
Group type: COMPARATOR
Intervention: Not informed about the prize-draw
Number of subjects: 433
Study 25111429 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interventions (BMIs)
Number of subjects: 249
Study 25111429 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 249
Study 25111429 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher therapist ratings of MI Spirit
Number of subjects: 249
Study 23453899 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 77
Study 23453899 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose, metronomic cyclophosphamide + methotrexate (CM)
Number of subjects: 77
Study 23453899 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PLD and CM
Number of subjects: 77
Study 21183370 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 3000 mg/day
Number of subjects: 39
Study 21183370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 19859541 — intervention group
Group type: EXPERIMENTAL
Intervention: DENV3 infection with low anti-DENV3 neutralizing activity (PRNT(50) <=50) and measurable DENV3 ADE activity
Number of subjects: 60
Study 19859541 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher weight-for-age in the first 3 months of life and at illness presentation
Number of subjects: 60
Study 19859541 — intervention group
Group type: EXPERIMENTAL
Intervention: DENV3 PRNT(50) >50
Number of subjects: 60
Study 17498015 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC sevoflurane (up to 5%)
Number of subjects: 20
Study 17498015 — intervention group
Group type: COMPARATOR
Intervention: 1 MAC halothane (up to 1.5%)
Number of subjects: 20
Study 15356567 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg once daily (monotherapy)
Number of subjects: 160
Study 15356567 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg once daily plus Montelukast 10 mg once daily (combined therapy)
Number of subjects: 160
Study 15356567 — intervention group
Group type: COMPARATOR
Intervention: Montelukast 10 mg once daily (monotherapy)
Number of subjects: 160
Study 15356567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 11668104 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (GTN) paste
Number of subjects: 40
Study 11668104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9678778 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (P)
Number of subjects: 24
Study 9678778 — intervention group
Group type: COMPARATOR
Intervention: Low-cholesterol diet (D)
Number of subjects: 24
Study 7985631 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula (n = 12)
Number of subjects: 29
Study 7985631 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (n = 6)
Number of subjects: 29
Study 2919572 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 20
Study 2919572 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cognitive strategy
Number of subjects: 20
Study 29993839 — intervention group
Group type: EXPERIMENTAL
Intervention: IGRSVD algorithm using randomized singular value decomposition (RSVD) and ODE-based optimization.
Number of subjects: 0
Study 29993839 — intervention group
Group type: COMPARATOR
Intervention: Existing SVD algorithm and PCA_CMI algorithm (control group).
Number of subjects: 0
Study 28433798 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 250 IU/kg daily during the first 6 days of life
Number of subjects: 39
Study 28433798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 23985135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (12 weeks)
Number of subjects: 37
Study 22814893 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (830 nm), 100 mW, applied for 20 s per point (5 J/cm²)
Number of subjects: 20
Study 22814893 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (placebo light)
Number of subjects: 20
Study 21971473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention groups (IGs) receiving weekly sessions of group‐based multicomponent cognitive intervention
Number of subjects: 39
Study 21971473 — intervention group
Group type: COMPARATOR
Intervention: Active control groups (CGs) receiving pencil‐paper exercises for self‐study
Number of subjects: 39
Study 21971473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention groups (IGs)
Number of subjects: 39
Study 19122109 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 0
Study 19122109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17406886 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (16-week walking training)
Number of subjects: 20
Study 14963471 — intervention group
Group type: COMPARATOR
Intervention: PT-141 (doses greater than 7 mg)
Number of subjects: 0
Study 14963471 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-141
Number of subjects: 0
Study 12074226 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening strips with 5.3% hydrogen peroxide bleaching gel (Crest Whitestrips)
Number of subjects: 57
Study 12074226 — intervention group
Group type: COMPARATOR
Intervention: Placebo strips without hydrogen peroxide
Number of subjects: 57
Study 9802373 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment
Number of subjects: 180
Study 9802373 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 180
Study 9802373 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% tacrolimus ointment
Number of subjects: 180
Study 9802373 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 180
Study 9802373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus-treated patients
Number of subjects: 180
Study 9802373 — intervention group
Group type: COMPARATOR
Intervention: Vehicle-treated patients
Number of subjects: 180
Study 7641661 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support during a stressful speech task
Number of subjects: 104
Study 7641661 — intervention group
Group type: COMPARATOR
Intervention: No social support during a stressful speech task
Number of subjects: 104
Study 2746750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 110
Study 2746750 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 110
Study 866705 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandins in a viscous medium
Number of subjects: 0
Study 866705 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study 31782828 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical screen during dressing changes (N = 26)
Number of subjects: 52
Study 31782828 — intervention group
Group type: COMPARATOR
Intervention: Regular dressing changes (Control group, N = 26)
Number of subjects: 52
Study 31637444 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy plus intrathecal liposomal cytarabine (median 5 injections, range 1-20)
Number of subjects: 73
Study 31637444 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy alone (control group)
Number of subjects: 73
Study 31637444 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy plus intrathecal liposomal cytarabine
Number of subjects: 73
Study 31637444 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life until progression
Number of subjects: 73
Study 29800954 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Radiotherapy (RT)
Number of subjects: 3213
Study 26712187 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy group
Number of subjects: 65
Study 26712187 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dairy group
Number of subjects: 65
Study 26712187 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 24024499 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR(cys)
Number of subjects: 4614
Study 24024499 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR(cr)
Number of subjects: 4614
Study 24024499 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR(cr-cys)
Number of subjects: 4614
Study 22663903 — intervention group
Group type: EXPERIMENTAL
Intervention: Mom‐Net (8‐session, Internet‐facilitated intervention)
Number of subjects: 70
Study 22663903 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention/facilitated treatment‐as‐usual (DI/TAU)
Number of subjects: 70
Study 20646514 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized group (midazolam 0.06 mg/kg, fentanyl 1 mg/kg at 1 min later, vecuronium 0.1 mg/kg at 1 min 55 s, propofol 1.5‐2 mg/kg at 2 min, second dose of 3 mg/kg fentanyl at 2 min 20 s)
Number of subjects: 120
Study 20646514 — intervention group
Group type: COMPARATOR
Intervention: Control group (fentanyl 4 mg/kg injected at time 1 min)
Number of subjects: 120
Study 18948243 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial lower sternotomy (group 1, n = 26)
Number of subjects: 82
Study 18948243 — intervention group
Group type: EXPERIMENTAL
Intervention: Right anterolateral thoracotomy via a submammary incision (group 2, n = 34)
Number of subjects: 82
Study 18948243 — intervention group
Group type: COMPARATOR
Intervention: Conventional median sternotomy (group 3, n = 22)
Number of subjects: 82
Study 15964387 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA) monitoring using limited sampling strategy (LSS)
Number of subjects: 9
Study 15964387 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA) monitoring using four samples
Number of subjects: 9
Study 11846843 — intervention group
Group type: EXPERIMENTAL
Intervention: Emdogain
Number of subjects: 28
Study 11846843 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 10527996 — intervention group
Group type: COMPARATOR
Intervention: Trimegestone-based sequential hormone replacement therapy (HRT) with doses of 0.05, 0.1, 0.25, and 0.5 mg per day of trimegestone from day 15 to day 28, combined with continuous micronized oestradiol 2 mg daily for six treatment cycles
Number of subjects: 0
Study 10527996 — intervention group
Group type: COMPARATOR
Intervention: Natural cycle (control group)
Number of subjects: 0
Study 7579312 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 1: rifampicin, isoniazid and pyrazinamide daily for an initial 3 months followed by rifampicin and isoniazid twice‐weekly for 6 months.
Number of subjects: 108
Study 7579312 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 2: rifampicin, isoniazid and pyrazinamide thrice‐weekly for an initial 3 months followed by rifampicin and isoniazid twice‐weekly for 6 months.
Number of subjects: 108
Study 7579312 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 1
Number of subjects: 108
Study 7579312 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 2
Number of subjects: 108
Study 7579312 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 108
Study 1789404 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed gloves
Number of subjects: 3
Study 1789404 — intervention group
Group type: COMPARATOR
Intervention: Non-washed gloves
Number of subjects: 3
Study 1789404 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterilized gloves (120 degrees C for 1 h in saturated steam)
Number of subjects: 3
Study 7138753 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 8
Study 7138753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol 80 mg
Number of subjects: 8
Study 7138753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7138753 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (twice a day for 2 weeks)
Number of subjects: 8
Study 7138753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (twice a day for 2 weeks)
Number of subjects: 8
Study 7138753 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (6 weeks treatment)
Number of subjects: 8
Study 7138753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (6 weeks treatment)
Number of subjects: 8
Study 31907032 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based therapy
Number of subjects: 0
Study 31907032 — intervention group
Group type: COMPARATOR
Intervention: Behavioral activation therapy
Number of subjects: 0
Study 31268130 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI/dMMR tumors
Number of subjects: 2630
Study 31268130 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oxaliplatin-based adjuvant chemotherapy regimens
Number of subjects: 2630
Study 31268130 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI/dMMR tumors lacking BRAFV600E
Number of subjects: 2630
Study 31268130 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI/dMMR tumors harboring BRAFV600E
Number of subjects: 2630
Study 31268130 — intervention group
Group type: COMPARATOR
Intervention: Tumors with BRAFV600E
Number of subjects: 2630
Study 31268130 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI/dMMR tumors with BRAFV600E
Number of subjects: 2630
Study 27037801 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoREZ
Number of subjects: 30
Study 27037801 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiV GP
Number of subjects: 30
Study 27037801 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus/gutta‐percha
Number of subjects: 30
Study 25631113 — intervention group
Group type: EXPERIMENTAL
Intervention: PINQ-PHONE (telephone questionnaire)
Number of subjects: 300
Study 25631113 — intervention group
Group type: COMPARATOR
Intervention: Negative responses to PINQ-PHONE
Number of subjects: 300
Study 25631113 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sensitivity of PINQ-PHONE
Number of subjects: 300
Study 25631113 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall specificity of PINQ-PHONE
Number of subjects: 300
Study 24420556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide plus concurrent and sequential sorafenib 200 mg orally bid for four cycles, then 400 mg orally bid as maintenance for up to 12 months after no disease progression.
Number of subjects: 18
Study 24420556 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and etoposide plus concurrent and sequential sorafenib.
Number of subjects: 18
Study 22758350 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pesticide-based shampoo
Number of subjects: 216
Study 22758350 — intervention group
Group type: COMPARATOR
Intervention: Malathion foam
Number of subjects: 216
Study 19121428 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete ST resolution
Number of subjects: 3425
Study 19121428 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ST resolution
Number of subjects: 3425
Study 19121428 — intervention group
Group type: EXPERIMENTAL
Intervention: No ST resolution
Number of subjects: 3425
Study 17312209 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg/kg administered by IV bolus after rocuronium-induced NMB under propofol anesthesia
Number of subjects: 42
Study 17312209 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg/kg administered by IV bolus after rocuronium-induced NMB under sevoflurane anesthesia
Number of subjects: 42
Study 17312209 — intervention group
Group type: COMPARATOR
Intervention: Control group (sevoflurane)
Number of subjects: 42
Study 15353025 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise (two 30-minute sessions per week for 8 weeks)
Number of subjects: 36
Study 15353025 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 36
Study 11280691 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational sessions run by local opinion leaders presenting guidelines on management of UAP from the National Health and Medical Research Council.
Number of subjects: 1872
Study 9557590 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistance of 0.20 kPa (R1)
Number of subjects: 9
Study 9557590 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistance of 0.29 kPa (R2)
Number of subjects: 9
Study 9557590 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistance of 0.39 kPa (R3)
Number of subjects: 9
Study 9557590 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistance of 0.49 kPa (R4)
Number of subjects: 9
Study 9557590 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 9
Study 8012746 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource loss
Number of subjects: 229
Study 3221375 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil 240 mg tablets
Number of subjects: 0
Study 3221375 — intervention group
Group type: COMPARATOR
Intervention: Office BP measurement
Number of subjects: 0
Study 3221375 — intervention group
Group type: COMPARATOR
Intervention: Day-time ambulatory monitoring
Number of subjects: 0
Study 30786304 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg of pethidine
Number of subjects: 200
Study 30786304 — intervention group
Group type: COMPARATOR
Intervention: 25 mg/kg of dipyrone
Number of subjects: 200
Study 27940313 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful condition (BE group)
Number of subjects: 103
Study 27940313 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-stressful condition (BE group)
Number of subjects: 103
Study 27940313 — intervention group
Group type: COMPARATOR
Intervention: Stressful condition (HC group)
Number of subjects: 103
Study 27940313 — intervention group
Group type: COMPARATOR
Intervention: Non-stressful condition (HC group)
Number of subjects: 103
Study 26405294 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised colistin (500000 U, thrice daily for 10 days)
Number of subjects: 168
Study 26405294 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS group, thrice daily for 10 days)
Number of subjects: 168
Study 26405294 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised colistin
Number of subjects: 168
Study 23849900 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with heat/steam generating sheet (Ex+HSGS)
Number of subjects: 150
Study 23849900 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat/steam generating sheet (HSGS)
Number of subjects: 150
Study 23849900 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (Ex)
Number of subjects: 150
Study 23849900 — intervention group
Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 150
Study 17001471 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 521
Study 17001471 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 200 mg once daily
Number of subjects: 521